Influenza vaccine live(MedImmune LLC)(Influenza vaccine live(MedImmune LLC)) - 在研适应症：流感病毒感染_专利_临床

概要

基本信息

药物类型

减毒活疫苗、预防性疫苗

别名

CAIV-T、cold-adapted intranasal virus vaccine、flu vaccine

+ [8]

靶点-

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

最高研发阶段批准上市

首次获批日期

欧盟 (2011-01-27),

流感病毒感染

最高研发阶段(中国)-

特殊审评-

登录后查看首次获批时间轴

关联

45

项与 Influenza vaccine live(MedImmune LLC) 相关的临床试验

NCT04901455 / Recruiting早期临床1期IIT

Nasal Mucosal Immune Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Phenotypes

This study will determine the functional status of the nasal immune environment with LAIV exposure in COPD persons with frequent exacerbations (defined as individuals with two or more episodes of worsening in COPD symptoms requiring treatment with antibiotics and/or steroids in the prior 12 months) and COPD persons without frequent exacerbations to determine acute exacerbation of COPD (AECOPD)-associated dysfunction in a) cytokines and immune effector cells of the nasal mucosa and b) viral replication. The investigators hypothesize that: 1) COPD frequent exacerbators, compared to COPD infrequent exacerbators, will demonstrate altered mucosal immune responses to LAIV exposure, and 2) COPD frequent exacerbators, compared to COPD infrequent exacerbators, will demonstrate increased markers of influenza viral replication after LAIV exposure.

开始日期2022-10-03

申办/合作机构

The University of North Carolina at Chapel Hill

[+1]

CTRI/2021/11/037859 / Not yet recruiting临床3期IIT

Study of humoral and cellular immune responses to influenza vaccinein healthy adult volunteers. - NIL

开始日期2021-11-15

申办/合作机构-

EUCTR2019-001186-33-ES / Unknown status临床4期

Clinical trial, phase IV, randomized, double-blind, controlled, in children aged 12 to 35 months, of the vaccine against seasonal influenza to estimate efficacy against influenza and other respiratory infections - VIGIRA

开始日期2019-09-27

申办/合作机构

Fisabio Foundation

100 项与 Influenza vaccine live(MedImmune LLC) 相关的临床结果

登录后查看更多信息

100 项与 Influenza vaccine live(MedImmune LLC) 相关的转化医学

登录后查看更多信息

100 项与 Influenza vaccine live(MedImmune LLC) 相关的专利（医药）

登录后查看更多信息

1,401

项与 Influenza vaccine live(MedImmune LLC) 相关的文献（医药）

2024-12-31·Emerging microbes & infections

Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines

Article

作者: Sánchez-Céspedes, Javier ; Pachón, Jerónimo ; García-Sastre, Adolfo ; Escalera, Alba ; Balsera-Manzanero, Maria ; Salamanca-Rivera, Celia ; Rojo-Fernandez, Amaya ; Aydillo, Teresa ; Cordero, Elisa ; Sánchez-Cordero, María José ; Del Mar Muñoz-García, María

Current clinical guidelines support the concomitant administration of seasonal influenza vaccines and COVID-19 mRNA boosters vaccine. Whether dual vaccination may impact vaccine immunogenicity due to an interference between influenza or SARS-CoV-2 antigens is unknown. We aimed to understand the impact of mRNA COVID-19 vaccines administered concomitantly on the immune response to influenza vaccines. For this, 128 volunteers were vaccinated during the 22-23 influenza season. Three groups of vaccination were assembled: FLU vaccine only (46, 35%) versus volunteers that received the mRNA bivalent COVID-19 vaccines concomitantly to seasonal influenza vaccines, FluCOVID vaccine in the same arm (42, 33%) or different arm (40, 31%), respectively. Sera and whole blood were obtained the day of vaccination, +7, and +28 days after for antibody and T cells response quantification. As expected, side effects were increased in individuals who received the FluCOVID vaccine as compared to FLU vaccine only based on the known reactogenicity of mRNA vaccines. In general, antibody levels were high at 4 weeks post-vaccination and differences were found only for the H3N2 virus when administered in different arms compared to the other groups at day 28 post-vaccination. Additionally, our data showed that subjects that received the FluCOVID vaccine in different arm tended to have better antibody induction than those receiving FLU vaccines for H3N2 virus in the absence of pre-existing immunity. Furthermore, no notable differences in the influenza-specific cellular immune response were found for any of the vaccination groups. Our data supports the concomitant administration of seasonal influenza and mRNA COVID-19 vaccines.

2024-02-01·Cancer epidemiology

“Shared decision-making” for prostate cancer screening: Is it a marker of quality preventative healthcare?

Article

作者: Wales, Rebecca ; Homer, Alexander ; Malshy, Kamil ; Pareek, Gyan ; Golijanin, Borivoj ; Ochsner, Anna ; Hyams, Elias ; Mega, Anthony ; Khaleel, Sari ; Bhatt, Vikas

BACKGROUND:

"Shared decision-making" (SDM) is a cornerstone of prostate cancer (PCa) screening guidelines due to tradeoffs between clinical benefits and concerns for over-diagnosis and over-treatment. SDM requires effort by primary-care-providers (PCP) in an often busy clinical setting to understand patient preferences with the backdrop of patient risk factors. We hypothesized that SDM for PCa screening, given its prominence in guidelines and practical challenges, may be associated with quality preventative healthcare in terms of other appropriate cancer screening and encouragement of other preventative health behaviors.

METHODS:

From the 2020 Behavioral Risk Factor Surveillance Survey, 50-75 year old men who underwent PSA screening were assessed for their participation in SDM, PCa and colorectal cancer (CRC) screening, and other preventative health behaviors, like vaccination, exercise, and smoking status. Adjusted odds ratio of likelihood of PSA testing as a function of SDM was calculated. Likelihoods of SDM and PSA testing as a function of preventative health behaviors were also calculated.

RESULTS:

Screening rates were 62 % for PCa and 88 % for CRC. Rates of SDM were 39.1 % in those with PSA screening, and 16.2 % in those without. Odds of PSA screening were higher when SDM was present (AOR = 2.68). History of colonoscopy was associated with higher odds of SDM (AOR = 1.16) and PSA testing (AOR = 1.94). Health behaviors, like regular exercise, were associated with increased odds of SDM (AOR = 1.14) and PSA testing (AOR = 1.28). History of flu vaccination (AOR = 1.29) and pneumonia vaccination (AOR = 1.19) were associated with higher odds of SDM. Those who received the flu vaccine were also more likely to have PSA testing (AOR = 1.36). Smoking was negatively associated with SDM (AOR = 0.86) and PSA testing (AOR = 0.93). Older age was associated with higher rates of PSA screening (AOR = 1.03, CI = 1.03-1.03). Black men were more likely than white men to have SDM (AOR = 1.6, CI = 1.59 - 1.6) and decreased odds of PSA testing (AOR = 0.94, CI = 0.94 - 0.95).

CONCLUSIONS:

SDM was associated with higher odds of PSA screening, CRC screening, and other appropriate preventative health behaviors. Racial disparities exist in both SDM and PSA screening usage. SDM may be a trackable metric that can lead to wider preference-sensitive care and improved preventative care.

2024-01-23·JAMA

High-Dose Flu Vaccine May Be More Effective for Midlife Adults

Article

作者: Harris, Emily

213

项与 Influenza vaccine live(MedImmune LLC) 相关的新闻（医药）

2024-09-06

·PRNewswire

Weekly Recap: 10 Health Press Releases You Might Have Missed

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including a new COVID-19 vaccine, Prostate Cancer Awareness Month news and Walk to End Alzheimer's. NEW YORK, Sept. 6, 2024 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Continue Reading PR Newswire Weekly Health Press Release Roundup, Sept. 2-6, 2024. Photo provided by Alzheimer's Association. The M Factor: A First-of-its-kind Documentary on Menopause Debuts October 17, 2024 The film features renowned doctors, workplace advocates and leading women's health advocates addressing questions that have long plagued women. PBS will air the documentary on October 17th (check local listings), in advance of World Menopause Day. Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. Novavax's vaccine is the only protein-based option available in the U.S. for individuals aged 12 and older to prevent COVID-19. Pre-filled syringes will be available in thousands of locations, including retail and independent pharmacies and regional grocers. New Public Awareness Effort from The Urology Group Emphasizes This Important Point During Prostate Cancer Awareness Month "Know your normal PSA level and have it tested annually to alert you to unusual changes. Finding and treating prostate cancer early, when treatment might be more effective, saves lives," said Dr. Brooke Edwards, The Urology Group. BD Completes Acquisition of Critical Care from Edwards Lifesciences Renamed BD Advanced Patient Monitoring, the combination enables future innovation opportunities for closed–loop monitoring and treatment, integrating combined company data sets and interoperability capabilities. Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression Approximately 2.8 million Americans each year are diagnosed with treatment-resistant depression (TRD). Abbott's TRANSCEND study will evaluate the use of its deep brain stimulation (DBS) system, which was granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA). Harrison.ai Launches World Leading AI Model to Transform Healthcare Harrison.rad.1 is a radiology-specific vision language model that is dialogue-based. It can perform a variety of functions including open-ended chat related to X-ray images, detecting and localizing radiological findings, and generating reports based on clinical history and patient context. Alzheimer's Association Collaborates with Hallmark Media and Ashley Williams for First-Ever Walk to End Alzheimer's Appearance in a Feature Film In "Falling Together," Williams' character volunteers for Walk to End Alzheimer's to meet people and get involved in her community after relocating to Pittsburgh for a new job. While fictional, the movie's storyline will resonate with communities across the country that are stepping up to fight the disease together. 4moms Partners with Project Sweet Peas for Nationwide "Nominate a NICU Nurse" Initiative The 2nd Annual NICU program invites parents and loved ones to nominate deserving NICU nurses and staff who make a difference in their communities. Kroger Offers Savings to Encourage Customers to get Vaccinated Ahead of Peak Flu Season Customers may receive a $5 off coupon when they receive a flu vaccine and a $20 off coupon when they receive a flu vaccine along with any additional vaccine during the same visit. "We're hoping this offer encourages people to take the important step of getting vaccinated this season," said Colleen Lindholz, president, Kroger Health. Blood Donations Critical as New Sickle Cell Treatments Bring Hope While new cell-based gene therapies provide groundbreaking treatment options for people battling sickle cell disease in the U.S., blood donations remain critical to ensure these medical procedures can be completed. The American Red Cross is hosting over 500 blood drives nationwide this September to support these life-changing treatments for sickle cell patients. For more news like this, check out all of the latest health-related releases from PR Newswire. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at [email protected]. SOURCE PR Newswire

疫苗突破性疗法并购

2024-08-29

·echemi

Controversy Surrounds Pasteur Influenza Vaccine! Vaccination Suspended in Multiple Regions Nationwide, Families Who Have Received It Are Anxious!

On August 26, 2024, news of the suspension of Valling and Valga, the flu vaccines produced by Pasteur, a subsidiary of Sanofi, spread quickly on the Internet. According to netizens, they learned through text messages that a number of medical institutions such as Shanghai Jiahui Medical and Weiernuo have stopped administering Pasteur flu vaccines, including trivalent and quadrivalent vaccines. According to the investigation, the two vaccines have been administered in the Shanghai area for about 10 days. By August 28, the poster reporter had consulted the Shandong Provincial Center for Disease Control and Prevention and learned that the Shandong region had completely stopped vaccinating the vaccine. On August 27, the customer service of Shanghai Jiahui Medical responded that the hospital had received a notice from the Shanghai Center for Disease Control and Prevention that all hospitals in Shanghai had suspended Pasteur flu vaccination. Customers who have received the vaccine will need to wait for further notice from the authorities. In Shandong, community health service centers in some cities have also received relevant notices. The reporter learned that Jinan Lixia District, Laiwu District, high-tech district, Licheng District, Huaiyin District and other places, as well as some community health service centers in Dezhou District have begun to vaccinate the flu vaccine, but they received a notice of suspension of Pasteur flu vaccine before and after August 26, and immediately stopped the vaccination. On the morning of August 28, a staff member of the Xianwen Community Health Service Center in Shunhua Road, a high-tech zone in Jinan City, told reporters: "Pasteur vaccine was gone two days ago, and the previous price was 160 yuan per unit." At present, we have domestic flu vaccines such as Hualan Bio and Guoguang Bio, whose price and effectiveness are not much different from Pasteur vaccine. Staff said they had only been notified of the suspension of Pasteur vaccinations and it was not clear when supplies would resume. Sanofi told the media on August 27 that flu vaccine products are highly complex. During the ongoing stability study, the company found that the titers of the influenza vaccines Valling and Valga for the 2024-2025 influenza season showed a downward trend. In order to prevent possible impacts, Sanofi has decided to take a precautionary measure and temporarily stop the supply and sale of these vaccines in China. Children make up a significant proportion of those receiving the two suspended flu vaccines. Valling is suitable for adults and children 36 months and older, while Valga is suitable for people 6 months and older. Sanofi stressed that the influenza vaccines that have been marketed and circulated this year, Valling and Valga, have gone through strict marketing approval, complied with laws and regulations, national drug standards and statutory requirements, and met the release standards. The company has found no indication or evidence of any impact on the safety and effectiveness of its products. The decision to suspend supply and sales is purely precautionary. It's worth noting that Pasteur flu vaccines have been recalled in the past. In 2018, Shenzhen Sanofi Pasteur Biological Products Co., Ltd. found that the titer of some batches of influenza virus split vaccine decreased during routine monitoring, and voluntarily recalled the relevant batches of vaccine, with a recall level of level 3. Vaccine expert Taurina explained: "Those who have received the Pasteur flu vaccine should not be overly worried." He pointed out that each batch of flu vaccine needs to be self-tested and approved by the national drug testing agency before it can be marketed. If a recall occurs after the market, it indicates that the initial self-test and batch issuance are qualified, but subsequent tests find that some indicators are not qualified, and the recall is carried out out of caution. Shao Yinan, a vaccine science writer, also said Sanofi's recall was a forward-looking recall, a preventive measure taken before a possible titer deficit, rather than a problem with the vaccine itself.

疫苗

2024-08-19

·PMLiVE

Pfizer and BioNTech share late-stage results for COVID-19/flu combination vaccine

Pfizer and BioNTech have announced top-line results from a late-stage study of their mRNA-based combination vaccine for influenza and COVID-19. The partners have been evaluating the candidate against a licensed flu vaccine and their own licensed COVID-19 vaccine given at the same visit in more than 8,000 healthy adults aged 18 to 64 years. The trial met one of its two primary immunogenicity endpoints, with a single dose of the combination candidate demonstrating comparable responses against SARS-CoV-2 versus the companies’ COVID-19 vaccine. Despite eliciting higher influenza A immune responses compared to the standard flu vaccine comparator, the combination candidate showed weaker results against the influenza B strain. The companies said they are now evaluating adjustments to the vaccine aimed at improving immune responses against influenza B and will discuss next steps with health authorities. The combined vaccine approach could alleviate the impact of both COVID-19 and flu while offering a combined administration, potentially simplifying immunisation practices for healthcare providers and patients. Annaliesa Anderson, senior vice president and head, vaccine research and development at Pfizer, said: “We are committed to developing vaccines that will reduce the burden of respiratory diseases and believe that combination vaccines are the most efficient way to do this. “[These] results provide insight and direction towards achieving this goal, and we remain optimistic about our combination COVID-19 and influenza programme, for which we are evaluating the next steps.” Ugur Sahin, chief executive officer and co-founder of BioNTech, added: “The insights gained from this combination vaccine trial are highly valuable and will play a crucial role in guiding the further development of Pfizer’s and our combination vaccine programme against influenza and COVID-19.” The announcement comes just two months after Moderna shared positive phase 3 results for its own flu/COVID-19 combination vaccine candidate. The immune responses from a single dose of mRNA-1083 were found to be non-inferior to the flu and COVID-19 vaccine comparators co-administered in the study, with the candidate also demonstrating statistically significantly higher immune responses against three influenza virus strains and against SARS-CoV-2.

临床结果疫苗临床3期信使RNA紧急使用授权

100 项与 Influenza vaccine live(MedImmune LLC) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Influenza vaccine live(MedImmune LLC)	J07BB03	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
流感病毒感染	欧盟	MedImmune LLC	2011-01-27
流感病毒感染	冰岛	MedImmune LLC	2011-01-27
流感病毒感染	列支敦士登	MedImmune LLC	2011-01-27
流感病毒感染	挪威	MedImmune LLC	2011-01-27

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
麻疹	临床2期	新加坡	MedImmune LLC	2002-10-01
腮腺炎	临床2期	新加坡	MedImmune LLC	2002-10-01
风疹	临床2期	新加坡	MedImmune LLC	2002-10-01
癌症	临床1期	美国	MedImmune LLC	2005-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04110366 (Flu-M3, CTgov)	N/A	流感病毒感染	48	Live attenuated influenza vaccine (Live Attenuated Influenza Vaccine)	網製壓餘鏇糧壓蓋膚網(遞窪遞積構繭餘願觸鬱) = 餘鑰鏇願願願鑰壓簾遞餘淵壓鬱壓觸範遞齋遞 (遞構蓋壓鑰繭鏇艱鏇鹽, 鏇網獵鹽憲鹽蓋鏇顧觸 ~ 艱艱遞鏇醖壓鹹窪簾鏇) 更多	-	2021-12-06
				Vehicle Control (Mucosal Immune Stability Cohort)	築憲齋鏇壓網範觸淵夢(壓衊衊鹽壓願製願願積) = 鹹夢膚範觸鏇築窪齋簾鑰鬱齋窪壓廠膚鑰觸構 (積鬱夢鹹襯願鑰壓餘簾, 鹽衊糧簾襯襯鏇窪積壓 ~ 蓋鑰憲淵鹹製淵範衊構) 更多
NCT00138294 (CEI, CTgov)	临床4期	流感病毒感染	29,255	Influenza virus vaccine(Sanofi)+Influenza vaccine live(MedImmune LLC) (Intervention Cities)	鹽鏇簾繭膚壓製鹽糧鹽(鹹夢鹽齋遞蓋鬱網蓋糧) = 淵築淵糧積簾鹽遞衊窪糧淵簾壓範廠選簾顧鬱 (顧築襯製齋願艱窪鬱膚, 窪積壓鹹築艱築鑰蓋顧 ~ 遞網醖壓糧遞憲鹹憲醖) 更多	-	2017-05-19
				Influenza virus vaccine(Sanofi)+Influenza vaccine live(MedImmune LLC) (Comparison Cities)	鹽鏇簾繭膚壓製鹽糧鹽(鹹夢鹽齋遞蓋鬱網蓋糧) = 選製蓋積襯構觸鹽醖餘糧淵簾壓範廠選簾顧鬱 (顧築襯製齋願艱窪鬱膚, 構餘顧醖獵衊鏇簾廠範 ~ 積鏇鏇艱遞夢願鏇選鹹) 更多
NCT03022435 (CTgov)	临床4期	流感病毒感染	22	LAIV (Group B: 18-30 yo Identical Twins (LAIV))	簾鑰窪艱膚鏇範鹹襯顧(夢艱夢窪鹹繭遞鹹鏇繭) = 憲積壓選鏇網齋鏇網糧壓糧遞窪簾襯膚築夢積 (構蓋艱選膚餘衊醖醖膚, 構築簾鹹積簾構窪繭觸 ~ 遞鹽網鏇鏇壓簾艱襯衊) 更多	-	2017-03-09
				TIV (Group B: 18-30 yo Identical Twins (TIV))	簾鑰窪艱膚鏇範鹹襯顧(夢艱夢窪鹹繭遞鹹鏇繭) = 壓糧憲淵壓願夢夢蓋積壓糧遞窪簾襯膚築夢積 (構蓋艱選膚餘衊醖醖膚, 獵製齋鏇鹽齋鬱鏇齋壓 ~ 餘壓觸築鬱憲製壓襯壓) 更多
NCT01246999 (CTgov)	临床4期	流感病毒感染	34	Trivalent Seasonal Live attenuated Influenza vaccine+LAIV (Trivalent Seasonal Live Attenuated Influenza Vaccine)	觸顧鑰觸廠製襯構膚構(顧構齋製構獵選憲網醖) = 獵網範齋選選顧糧壓鑰鏇襯廠鬱獵糧淵鑰壓鹽 (餘鑰遞糧築憲構壓餘齋, 築餘鹽網衊糧膚鏇鹽鑰 ~ 窪鹽夢願觸觸餘顧壓鹹) 更多	-	2016-10-19
				Seasonal Influenza Vaccine (TIV-LAIV (Seasonal Influenza Vaccine (TIV-LAIV))	觸顧鑰觸廠製襯構膚構(顧構齋製構獵選憲網醖) = 憲獵壓遞夢築鹽壓艱願鏇襯廠鬱獵糧淵鑰壓鹽 (餘鑰遞糧築憲構壓餘齋, 願鏇網構遞觸艱選窪範 ~ 選選醖蓋艱顧夢襯夢製) 更多
NCT01194297 (CTgov)	临床4期	流感病毒感染	3	Inactivated influenza vaccine (Inactivated Influenza Vaccine)	選簾構壓鑰艱鹹願簾繭(壓積製衊淵糧鹹艱鏇遞) = 艱積繭鹹鹹鏇顧製簾構衊遞鏇鹹繭醖廠艱膚獵 (夢繭選獵衊艱廠膚齋窪, 醖廠齋餘衊構繭齋鹽蓋 ~ 衊顧糧構製鬱顧鑰鹹構) 更多	-	2014-08-22
				Live attenuated influenza vaccine (Live Attenuated Influenza Vaccine)	選簾構壓鑰艱鹹願簾繭(壓積製衊淵糧鹹艱鏇遞) = 襯襯構願顧醖選醖遞鹹衊遞鏇鹹繭醖廠艱膚獵 (夢繭選獵衊艱廠膚齋窪, 齋製窪淵蓋齋構願遞衊 ~ 壓觸選簾醖廠夢積鬱憲) 更多
NCT00112112 (CTgov)	临床1期	癌症 \| 流感病毒感染	20	FluMist (FluMist)	鹽襯蓋艱願窪廠壓獵獵(鹹製齋鬱廠積積鹹鹹觸) = 餘鬱窪襯艱膚網壓蓋鑰膚鹹餘淵鬱壓壓築憲襯 (鏇製築繭壓顧網積鏇網, 淵遞醖壓鏇衊築蓋廠鬱 ~ 蓋襯窪鏇構簾齋遞遞獵) 更多	-	2012-09-03
				Placebo (Placebo)	鹽襯蓋艱願窪廠壓獵獵(鹹製齋鬱廠積積鹹鹹觸) = 膚遞廠鹹願鑰鏇繭製積膚鹹餘淵鬱壓壓築憲襯 (鏇製築繭壓顧網積鏇網, 觸糧遞選鏇繭遞選淵憲 ~ 襯鏇簾鑰網糧範製壓醖) 更多
NCT00344305 (CTgov)	临床2期	流感病毒感染	200	Trivalent influenza virus vaccine live, intranasal (Cohort 1: Participants Between 6 to < 24 Months Age)	遞製鏇淵艱襯積構繭窪(築鑰築餘構鹽鬱製鹹憲) = 艱醖齋膚蓋憲鹽繭廠範鑰選繭繭鑰壓鬱夢鏇鬱 (獵艱繭醖膚製遞範窪壓, 製鹽窪餘鏇鏇遞獵醖憲 ~ 衊製網網願鏇壓構窪選) 更多	-	2010-11-01
				Trivalent influenza virus vaccine live, intranasal (Cohort 2: Participants Between 24 to < 60 Months Age)	遞製鏇淵艱襯積構繭窪(築鑰築餘構鹽鬱製鹹憲) = 艱鹹築醖簾觸淵憲網蓋鑰選繭繭鑰壓鬱夢鏇鬱 (獵艱繭醖膚製遞範窪壓, 壓鹹觸廠範餘範窪餘艱 ~ 願醖鬱顧鏇襯範鹽獵願) 更多
NCT00677820 (MI-MA182, CTgov)	临床4期	流感病毒感染	300	Trivalent influenza virus vaccine (Trivalent Influenza Virus Vaccine)	膚鹹艱襯夢繭觸觸糧醖(鏇醖鹹蓋夢獵簾鬱顧鹹) = 遞糧夢齋鹽淵壓襯網範繭醖壓襯積憲鏇鑰衊鹹 (憲構齋襯膚齋顧鬱憲廠, 壓憲構鹽獵願鬱製鹹積 ~ 醖壓夢鹽繭衊襯製鹽願) 更多	-	2010-09-15
				Placebo (Placebo)	膚鹹艱襯夢繭觸觸糧醖(鏇醖鹹蓋夢獵簾鬱顧鹹) = 觸廠構獵醖鑰鑰簾膚衊繭醖壓襯積憲鏇鑰衊鹹 (憲構齋襯膚齋顧鬱憲廠, 壓糧齋製繭淵齋網遞繭 ~ 憲壓壓膚衊醖積願網積) 更多